Board of Directors
Erez AminovChairman
Erez Aminov is the Chairman and Chief Executive Officer of Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a biotechnology company pioneering age-reversal science. Under his leadership, Telomir has advanced innovative therapies targeting age-related conditions, including Type 2 Diabetes, aging, and Progeria—a rare and fatal genetic disorder characterized by accelerated aging in children. Mr. Aminov has successfully guided Telomir through multiple preclinical trials, secured critical funding, and built a high-performing team dedicated to advancing transformative solutions in regenerative medicine.
In addition to his leadership at Telomir, Mr. Aminov serves as Chairman and Chief Executive Officer of MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), a biopharmaceutical company developing groundbreaking treatments for neuropsychiatric disorders. At MIRA, he has been instrumental in advancing key therapies such as MIRA55 and Ketamir-2, securing funding, and leading the company to the submission of an Investigational New Drug (IND) application. His strategic guidance played a central role in MIRA’s successful initial public offering (IPO), establishing it as a leader in its field.
With a wealth of experience in biotechnology consulting, investment, and leadership, Mr. Aminov also founded Locate Venture Corp, where he supported early-stage biotech enterprises. He has been a driving force behind the IPOs of both MIRA Pharmaceuticals and Telomir Pharmaceuticals, demonstrating his expertise in navigating complex regulatory and financial landscapes.
Mr. Aminov holds a Bachelor of Arts in Accounting from Touro University in New York. His unique blend of strategic vision, financial expertise, and commitment to advancing life-changing therapies has positioned Telomir Pharmaceuticals at the forefront of age-reversal science.
In addition to his leadership at Telomir, Mr. Aminov serves as Chairman and Chief Executive Officer of MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), a biopharmaceutical company developing groundbreaking treatments for neuropsychiatric disorders. At MIRA, he has been instrumental in advancing key therapies such as MIRA55 and Ketamir-2, securing funding, and leading the company to the submission of an Investigational New Drug (IND) application. His strategic guidance played a central role in MIRA’s successful initial public offering (IPO), establishing it as a leader in its field.
With a wealth of experience in biotechnology consulting, investment, and leadership, Mr. Aminov also founded Locate Venture Corp, where he supported early-stage biotech enterprises. He has been a driving force behind the IPOs of both MIRA Pharmaceuticals and Telomir Pharmaceuticals, demonstrating his expertise in navigating complex regulatory and financial landscapes.
Mr. Aminov holds a Bachelor of Arts in Accounting from Touro University in New York. His unique blend of strategic vision, financial expertise, and commitment to advancing life-changing therapies has positioned Telomir Pharmaceuticals at the forefront of age-reversal science.
Matthew P. Del Giudice, M.D.Director
Dr. Matthew P. Del Giudice, age 42, has practiced as a radiologist since 2014. He currently serves as a general overnight emergency radiologist at the Cleveland Clinic. Since March 2024, he has also served as a director of MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA). Prior to joining the Cleveland Clinic, from March 2021 to May 2022, Dr. Del Giudice was a general radiologist with Radiology and Imaging Specialists in Phoenix, Arizona. From July 2015 to February 2021, Dr. Del Giudice was a radiologist with Radiology Partners Phoenix, and from July 2014 to June 2015, he practiced as a musculoskeletal radiologist at the University of Arizona Health Sciences Center – Tucson. Dr. Del Giudice received his B.S. from the University of Illinois at Urbana-Champaign, his M.D. from Loyola University Stritch School of Medicine, completed his radiology residency at Loyola University Medical Center, and his musculoskeletal radiology fellowship at the University of Arizona Health Sciences Center – Tucson. Dr. Del Giudice is licensed to practice medicine in Florida and Ohio. We believe that Dr. Del Giudice is qualified to serve as one of our directors based on his extensive experience as a radiologist.
Ned MacPhersonDirector
Ned MacPherson, age 36, currently serves as Chief Growth Officer for Power Digital, an industry leading digital marketing agency. Since March 2024, he has also served as a director of MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA). Prior to joining Power Digital, from May 2016 to December 2023, he served as CEO and Head of Growth for Endrock Growth & Analytics, a company he founded and sold to Power Digital. Prior to founding Endrock Growth & Analytics, Mr. MacPherson held senior marketing and leadership positions at sunglass maker Prive Revaux (March 2018 to April 2020), curated meal company Menud (October 2014 to April 2018) and Rejuvenetics, LLC, a distributor of health and wellness products (December 2012 to March 2016). Mr. Macpherson holds a BA in Economics from Gettysburg College. We believe that Mr. MacPherson is qualified to serve as one of our directors based on his extensive experience assisting growth for early-stage companies.
Matthew Pratt Whalen, CPADirector
Matthew Pratt Whalen, CPA, age 45, is a Certified Public Accountant with over two decades of experience in public accounting and corporate finance. Mr. Whalen currently serves as the Chief Financial Officer of Power Digital Marketing Inc., an industry leading digital marketing agency, where he has driven significant revenue growth and led key financial transactions. Specifically, Mr. Whalen oversees the finance team, manages tax and audit relationships, and handles treasury management. Prior to joining Power Digital, from 2010 to May 2021, Mr. Whalen was the Chief Financial Officer of MRC Smart Technology Solutions, a subsidiary of Xerox Corporation where he played a pivotal role in growing the company’s revenue and managed diverse teams across multiple departments. Mr. Whalen holds a B.A. in Accounting from the University of San Diego and is a Certified Public Accountant in California. Mr. Whalen has also served on the Finance Committee of United Way San Diego. We believe that Mr. Whalen is qualified to serve as one of our directors based on his extensive experience in finance and as a Certified Public Accountant. Mr. Whalen has also served as a director of MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA).